Daiichi Sankyo has patented a novel peptide (SPINK2 mutant) that binds to active human MMP-9 but not to pro human MMP-9. The peptide has a specific amino acid sequence and shows potential in targeting active proteases. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Peptide binding to active mmp-9, not pro mmp-9
The granted patent (Publication Number: US11926655B2) discloses a novel SPINK2 mutant peptide that has the ability to bind to active human MMP-9 while not binding to pro human MMP-9. This peptide, as described in the claims, specifically targets the catalytic domain of active human MMP-9 and inhibits its protease activity. Importantly, the inhibition is shown to be specific to human MMP-9, highlighting the potential therapeutic applications of this peptide in targeting this specific enzyme.
Furthermore, the patent claims also describe additional features of the peptide, including specific amino acid sequences linked to the N-terminal and C-terminal ends of the peptide, as well as the presence of three disulfide bonds, a loop structure, an a-helix, and a ß-sheet within the peptide structure. The patent also covers compositions comprising the SPINK2 mutant peptide, indicating the potential for developing pharmaceutical compositions based on this novel peptide. Overall, the patent reveals a promising new approach for targeting human MMP-9 activity, with potential implications for the development of therapeutic interventions in conditions where MMP-9 dysregulation plays a role.
To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
